Meant to reply to your last post. Absolutely agree this is a screaming buy at these levels. Sure, the covid nasal spray would have/could have been a monster for ALT, but when? At how much cost? And what happens if it fails in Phase III trials after all that time and money? Dropping AdCovid now and focusing on the obesity drug is smart business move. From what we've seen in the early results, this could be a game changer. Still early, but if results stay this strong moving forward, ALT will have a big pharma partner or be bought out long before going through all the clinical trials. Like all biotech, there's risk with ALT. But the risk/reward here makes ALT a strong buy in my opinion. Down here in the $8s it's a crazy strong buy
News 
Market Data 
Discover 
